kabutan

Kringle Pharma,Inc.(4884) Summary

4884
TSE Growth
Kringle Pharma,Inc.
390
JPY
+3
(+0.78%)
Jan 29, 1:04 pm JST
2.54
USD
Jan 28, 11:04 pm EST
Result
PTS
outside of trading hours
388.9
Jan 29, 12:43 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.23
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
387 JPY 2.52 USD
Previous Close Jan 28
387 JPY 2.53 USD
High Jan 29, 12:43 pm
390 JPY 2.54 USD
Low Jan 29, 9:02 am
385 JPY 2.51 USD
Volume
15,400
Trading Value
6.00M JPY 0.04M USD
VWAP
387.03 JPY 2.53 USD
Minimum Trading Value
39,000 JPY 254 USD
Market Cap
2.85B JPY 0.02B USD
Number of Trades
25
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
244
1-Year High Jun 12, 2025
3,785
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 953,300
Jan 16, 2026 0 935,600
Jan 9, 2026 0 953,600
Dec 26, 2025 0 921,000
Dec 19, 2025 0 917,400
Company Profile
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein.
Sector
Pharmaceuticals
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein. The company is currently conducting clinical trials for acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. For acute spinal cord injury, a Phase III trial is in progress, aiming for a marketing authorization application. For ALS, the company is analyzing the results of a Phase II trial. A Phase III trial is underway for vocal cord scarring, while plans for the next phase of trials for acute kidney injury are being developed. Leveraging the neuroprotective and anti-fibrotic effects of HGF, Kringle Pharma aims to expand its applications to multiple intractable diseases. The company is also strengthening its new pipeline through collaborative research with universities and other companies.